Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
DIPYRIDAMOLE
LTT Pharma Limited
200 Milligram
Capsules Modified Release
2011-08-26
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Persantin Retard 200mg Modified-release Capsules, Hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains dipyridamole 200 mg For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Modified-release Capsules, Hard _Product imported from the UK:_ Hard gelatin capsules consisting of a red cap and an orange body. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Secondary prevention of ischaemic stroke and transient ischaemic attacks either alone or in conjunction with aspirin. As an adjunct to oral anti-coagulation for prophylaxis of thromboembolism associated with prosthetic heart valves. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults, including the Elderly_ One capsule twice daily, usually one in the morning and one in the evening, preferably with meals. The capsules should be swallowed whole without chewing. _Children_ Persantin Retard is not suitable for use in children. 4.3 CONTRAINDICATIONS Hypersensitivity to any components of the product. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Among other properties, dipyridamole acts as a potent vasodilator. It should therefore be used with caution in patients with severe coronary artery disease including unstable angina and recent myocardial infarction, left ventricular outflow obstruction or haemodynamic instability (e.g. decompensated heart failure). Clinical experience suggests that patients being treated with oral dipyridamole who also require pharmacological stress testing with intravenous dipyridamole should discontinue drugs containing oral dipyridamole for twenty-four hours prior to stress testing. Failure to do so may impair the sensitivity of the test. In patients with myasthenia gravis, readjustment of therapy may be necessary during treat Citiți documentul complet